Review article: Integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1095-1103

  Danese, S ^a   Siegel, C A ^b   Peyrin Biroulet, L ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BUDESONIDE MULTI MATRIX SYSTEM; BUDESONIDE-MMX; CORTICOSTEROID; HYDROCORTISONE; MESALAZINE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALGORITHM; CONTROLLED DRUG RELEASE; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FLATULENCE; HEADACHE; HEALING; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAINTENANCE THERAPY; MUCOSAL HEALING; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTAL IRRITATION; RECTUM DISEASE; REMISSION; REVIEW; SYSTEMIC THERAPY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; GLUCOCORTICOIDS; HUMANS; MESALAMINE; SEVERITY OF ILLNESS INDEX;

EID: 84898853766     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12712     Document Type: Review

References (59)

1. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
2. Lichtenstein GR, Bengtsson B, Hapten-White L, et al,. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther 2009; 29: 643-53.
3. Rutgeerts P, Lofberg R, Malchow H, et al,. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
4. Sandborn WJ, Lofberg R, Feagan BG, et al,. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005; 100: 1780-7.
5. Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
6. Sandborn WJ, Travis S, Moro L, et al,. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: e1-2.
7. Travis SP, Danese S, Kupcinskas L, et al,. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-41.
8. Feagan BG, Macdonald JK,. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000543.
9. Ford AC, Achkar JP, Khan KJ, et al,. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-16.
10. Marshall JK, Irvine EJ,. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293-300.
11. Ford AC, Khan KJ, Achkar JP, et al,. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 167-76.
12. Lichtenstein GR, Ramsey D, Rubin DT,. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011; 33: 672-8.
13. Sandborn WJ, Regula J, Feagan BG, et al,. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: e1-3.
14. Feagan BG, Macdonald JK,. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000544.
15. Marshall JK, Thabane M, Steinhart AH, et al,. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 11: CD004118.
16. Ford AC, Khan KJ, Sandborn WJ, et al,. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastro-enterol 2011; 106: 2070-7.
17. Zhu Y, Tang RK, Zhao P, et al,. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2012; 24: 487-94.
18. Sandborn WJ, Kamm MA, Lichtenstein GR, et al,. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26: 205-15.
19. Nikfar S, Rahimi R, Rezaie A, et al,. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009; 54: 1157-70.
20. Gisbert JP, Gonzalez-Lama Y, Mate J,. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13: 629-38.
21. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
22. Travis SP, Stange EF, Lemann M, et al,. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
23. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
24. Ford AC, Bernstein CN, Khan KJ, et al,. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 590-9.
25. Angus P, Snook JA, Reid M, et al,. Oral fluticasone propionate in active distal ulcerative colitis. Gut 1992; 33: 711-4.
26. Bossa F, Latiano A, Rossi L, et al,. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008; 103: 2509-16.
27. Lennard-Jones JE, Longmore AJ, Newell AC, et al,. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 217-22.
28. Rizzello F, Gionchetti P, D'Arienzo A, et al,. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002; 16: 1109-16.
29. Lewis JD, Gelfand JM, Troxel AB, et al,. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1428-35.
30. Lichtenstein GR, Feagan BG, Cohen RD, et al,. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
31. Rutgeerts PJ,. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1515-25.
32. Da Silva JA, Jacobs JW, Kirwan JR, et al,. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-93.
33. Hoes JN, Jacobs JW, Verstappen SM, et al,. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009; 68: 1833-8.
34. Adachi JD, Rostom A,. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 200-11.
35. Valentine JF, Sninsky CA,. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 878-83.
36. Edsbacker S, Bengtsson B, Larsson P, et al,. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 2003; 17: 525-36.
37. Edsbacker S, Larsson P, Wollmer P,. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. Eur J Gastroenterol Hepatol 2002; 14: 1357-62.
38. Hvizdos KM, Jarvis B,. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000; 60: 1141-78.
39. Seow CH, Benchimol EI, Griffiths AM, et al,. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 3: CD000296.
40. Sherlock ME, Seow CH, Steinhart AH, et al,. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; 10: CD007698.
41. Bar-Meir S, Chowers Y, Lavy A, et al,. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115: 835-40.
42. Campieri M, Ferguson A, Doe W, et al,. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 209-14.
43. Greenberg GR, Feagan BG, Martin F, et al,. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-41.
44. Tremaine WJ, Hanauer SB, Katz S, et al,. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002; 97: 1748-54.
45. Ferguson A, Campieri M, Doe W, et al,. Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998; 12: 175-83.
46. Greenberg GR, Feagan BG, Martin F, et al,. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110: 45-51.
47. Hanauer S, Sandborn WJ, Persson A, et al,. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 363-71.
48. Lofberg R, Rutgeerts P, Malchow H, et al,. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996; 39: 82-6.
49. Kozuch PL, Hanauer SB,. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-77.
50. Brunner M, Ziegler S, Di Stefano AF, et al,. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006; 61: 31-8.
51. Kamm MA, Lichtenstein GR, Sandborn WJ, et al,. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902.
52. Kamm MA, Sandborn WJ, Gassull M, et al,. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75.
53. Lichtenstein GR, Kamm MA, Boddu P, et al,. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102.
54. Brunner M, Vogelsang H, Greinwald R, et al,. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 463-70.
55. D'Haens GR, Kovacs A, Vergauwe P, et al,. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010; 4: 153-60.
56. Lichtenstein GR, Danese S, Ballard ED, et al,. Effect of budesonide MMX 6 mg on the hypothalamic-pituitary-adrenal (HPA) axis in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology 2012; 142 (Suppl. 1): S785.
57. Travis S, Danese S, Ballard ED, et al,. Safety analysis of budesonide MMX 6 mg used for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology 2012; 142 (Suppl. 1): S566-7.
58. Danese S, Kupcinskas L, Ballard ED, et al,. Budesonide MMX efficacy is independent of previous mesalazine exposure in ulcerative colitis: pooled analysis of CORE I and CORE II. 21st United European Gastroenterology Week. Berlin, Germany, 2013.
59. Travis SP, Danese S, Kupcinskas L, et al,. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-41.